ArticleAnnals of medicine2025
Risk factors of linezolid-associated hyponatremia from a retrospective case-control study: decreased serum albumin as a selective predictor in elder patients.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of linezolid-associated hyponatremia is approximately 20% in real-world studies. However, there are limited case reports and rare research on linezolid-induced hyponatremia. This study aims to identify risk factors associated with linezolid-induced hyponatremia, particularly in older patients.
methodsThis retrospective study was conducted from January 2018 to December 2023. Patients aged over 18 years who received linezolid for at least three days at Beijing Hospital were included. Statistical analyses were performed using SPSS Statistics version 19.
results68 patients were identified in the hyponatremia group, with 68 matched individuals by sex and age in the control group. Binary logistic regression analysis revealed that a history of cardiovascular disease, estimated glomerular filtration rate, and the duration of linezolid therapy were risk factors for hyponatremia. Subgroup analysis in patients age ≥ 65 identified the duration of therapy, a history of cardiovascular disease, a history of endocrine diseases, and serum albumin (ALB) decreased during linezolid therapy as key indicators of hyponatremia.
conclusionA decrease in ALB during linezolid therapy is a more selective predictor of hyponatremia than baseline ALB. Linezolid-induced hyponatremia is associated with adverse outcomes, highlighting the importance of monitoring serum sodium and ALB in patients receiving this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.